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Abstract
Objective: Large administrative databases may prove useful to assess epilepsy-related comorbidity
and mortality. Despite their increased use, their validity as data source in epilepsy is yet under-
ascertained.
Methods: Achmea is a large Dutch health insurance company covering about 25% of the population.
We performed a retrospective cohort study using data from the Achmea Health Insurance Database
(AHID) over the period 2006-2009. To assess the validity of epilepsy codes in the AHID, we randomly
invited 1000 individuals (age 18-75 years insured by Achmea), attending an epilepsy centre or a
district hospital during 2006-2009, to participate. Informed consent was provided by 293 eligible for
inclusion. We compared the diagnostic codes for epilepsy in AHID with the diagnosis in their case-
notes (reference standard). As additional measure of validity, we compared prevalence of epilepsy
codes in AHID (based on anonymized data of all 26.297 subjects with this code in AHID) with epilepsy
prevalence rates in the general Dutch population to estimate an age-specific standardized prevalence
ratio.
Results: We identified 293 participants with an epilepsy code in AHID. The majority (278) of them had
a definite or possible diagnosis of epilepsy in the case-notes; i.e. a positive predictive value of 0.95 (95%
CI 0.92-0.97). The overall prevalence of epilepsy codes in the AHID was slightly higher than the putative
prevalence in the general Dutch population (7.4/1.000 vs. 6.8/1.000) with a Standardized Prevalence
Ratio of 1.08 (95% CI: 1.08-1.09).
Conclusions: Our findings establish the validity of AHID data for a diagnosis of epilepsy and confirm
previous work on using administrative data for epilepsy research.
Keywords: epilepsy, administrative health data, accuracy, prevalence
Introduction
Epilepsy is a neurological condition characterized by recurring seizures usually requiring antiepileptic
drugs (AED). (Loscher and Schmidt, 2011; Sander, 2003) People with epilepsy often have comorbid
conditions. (Gaitatzis et al., 2012; Hermann et al., 2008; Keezer et al., 2016) The risk of premature
mortality is 2-3 times higher than in the general population. (Neligan et al., 2011) Premature
mortality may be explained by several factors such as epilepsy-related causes including accidents,
Sudden Unexpected Death in Epilepsy (SUDEP), or may be related to comorbid conditions such as a
cerebrovascular disease. (Novy et al., 2013; Surges et al., 2009) Precise figures on epilepsy mortality
and comorbidity are, however, still needed. Case-control studies in high risk populations (from
specialized epilepsy centres) may suffer from selection bias, small sample sizes and a disregard of
comorbid conditions. Population-based cohorts are also often limited by relative small samples of
the epilepsy population and have a too long study run time for surveillance of the actual burden and
risk profiles of epilepsy-related comorbidities and mortality.
Large population based studies using administrative health insurance data provide opportunities to
increase power of data and obtain comprehensive surveillance data. (England et al., 2012; Hesdorffer
et al., 2013; Smeets et al., 2011) This “big data” approach has been successfully used to address
epilepsy-related questions, e.g. concerning psychiatric comorbidity in premature mortality (Fazel et
al., 2013) or epilepsy-related psychiatric and somatic comorbidities e.g. migraine, autism, stroke,
diabetes. (Chen et al., 2011; Chou et al., 2016; Oh et al., 2017; Selassie et al., 2014; Sundelin et al.,
2016; Wannamaker et al., 2015) Previous work validated the diagnostic codes for epilepsy from
administrative databases. (Christensen et al., 2007; Ertl et al., 2016; Jette et al., 2010; Parko and
Thurman, 2009; Reid et al., 2012) Yet the validity of epilepsy diagnostic codes using health insurance
databases is still under-ascertained and needs confirmation in every database given the variety in
health care and coding systems. (Thurman et al., 2011)
Dutch health insurance databases are a potentially useful source for epilepsy research. The
Netherlands has a health care system with a mandatory and ubiquitous health insurance coverage.
Insurers register all reimbursed health care visits based on diagnostic codes provided by the treating
physician. (Braithwaite et al., 2017; Schoen et al., 2007) We assessed the validity of diagnostic codes
for epilepsy derived from Achmea, one of the major health insurance companies in the Netherlands.
The Achmea Health Insurance Database (AHID) was previously found representative of the health
care utilization of the total Dutch population with respect to age, gender and socioeconomic status.
(Smeets et al., 2011) We assessed accuracy by comparing diagnostic codes for epilepsy in AHID with
the diagnosis in case-notes (reference standard). As additional measure of validity, we compared the
prevalence of epilepsy codes in AHID with epilepsy prevalence rates in the general Dutch population.
Methods
Population and setting
Retrospective cohort data, with respect to demographics and health care utilization over the period
2006-2009, was retrieved from AHID, which covers around 4.1 million policyholders (25% of the total
Dutch population). All health care reimbursement claims are collected and continuously monitored to
ensure an accurate and valid database. (Smeets et al., 2011) During the period 2006-2009 the yearly
average number of people ≥ 18 years in AHID was 3.247.887.  
To assess the validity of the diagnostic epilepsy codes, we set to enrol around 1% of epilepsy cases in
AHID based on an estimated prevalence of 0.7% (Gommer AM, 2010). From two hospital registries: 1)
a tertiary epilepsy referral centre and 2) a district hospital, we selected all individuals with at least
one epilepsy-related visit to a neurologist between 2006 and 2009. This selection was made using the
hospital based claims database. All subjects aged 18-75 years, insured by Achmea for at least one
year during the study period, were eligible. Those with incomplete contact details and those in
residential care were excluded. Of 2916 potentially eligible subjects, we randomly invited by post,
1000 (70% from tertiary care and remaining from the district hospital) to participate. This included an
information letter and a request to provide informed consent to access their case-notes and AHID
data for comparison. A total of 293 respondents were eligible for inclusion.
We also had access to anonymized AHID data of all 26.297 adults with an epilepsy diagnostic code in
the same period. This allowed the delineation of the AHID epilepsy-cohort and to estimate epilepsy
prevalence amongst them. The study was fully compliant with Dutch regulations and approved by the
Medical Ethics Committee of Leiden University Medical Center and by Achmea’s Scientific and Privacy
Committee.
Data collection
AHID data included demographics (sex, year of birth and death (if applicable) and duration of
insurance by Achmea) and health care utilization over the period of interest. This included
information on all primary, secondary and tertiary care visits and drug prescriptions (ATC codes and
number of daily defined dose (DDD)), with corresponding dates. Hospital visits are coded by a
Diagnostic Treatment Protocol (DTP, in Dutch: ‘Diagnose Behandel Combinatie’): an administrative
code combining hospital registration of diagnoses (International Classification of Disease 9th revision
(ICD-9) with therapeutic interventions i.e. classification in generalized and focal epilepsy based on the
ICD 345.xx coding for epilepsy. For all participants in the validation subset, we requested a personal
identifiable code to link the AHID data to information retrieved from the case-notes.
Clinical data for the period participants were insured by Achmea were extracted from the hospital
case-notes. This included information on epilepsy diagnosis (history, seizure description, MRI, EEG
etc.), antiepileptic drug (AED) use, comorbid conditions and co-medication. Neurological diagnosis
were classified into three categories: (1) definite or probable epilepsy in case diagnostic work-up of
the treating neurologist supported a diagnosis and no alternative diagnosis suggested (Thurman et
al., 2011); (2) suspect epilepsy in case epilepsy was thought most likely but other alternatives were
considered (Thurman et al., 2011) (3) no epilepsy in case other conditions like syncope or psychogenic
non-epileptic seizures were considered to most likely. For each category, we recorded whether AED
were prescribed (i.e. all drugs within the AED subgroup of the ATC classification system except for
benzodiazepines), thus resulting in a total of six categories expressing the likelihood of the epilepsy
diagnosis including its treatment status. From the AHID we included all those with a DTP for
(generalized and focal) epilepsy, corresponding to the ICD 345.xx codes for epilepsy and treatment
status. Data extraction and classification was performed by one author (MW). An audit was
performed on a subset by RT and JC to minimize potential misclassification. In case of uncertainty RT
& JC reviewed and discussed to reach consensus.
Statistical analysis
We assessed baseline demographics, epilepsy and AED prescription data. The validation subset was
compared to the total number of epilepsy cases, aged 18-75 years, in AHID to assess the
representativeness of our sample. The prevalence of epilepsy in AHID was compared to epilepsy
prevalence data of Statistics Netherlands based on DTP codes for epilepsy in the general population.
(CBSStatline) An age-specific standardized prevalence ratio and 95% CI was calculated.
We assessed the percentage of correct DTPs for epilepsy in AHID validation subset by comparing
them to the reference standard (case-notes). Its positive predictive value (PPV and 95% CI) is
presented as measure of diagnostic accuracy (number of correctly classified cases). The PPV refers to
the proportion of epilepsy cases (category 1-3 from the case-notes) from all those identified with a
DTP for epilepsy in the AHID. As a sensitivity analysis we assessed the effect of reclassifying suspect
cases (category 3 or 4) as epilepsy or as non-epilepsy cases. All statistical analyses were performed
with IBM SPSS Statistics for Windows, version 22.0 (Armonk, NY: IBM Corp).
Results
A total of 293 respondents had a diagnostic code for epilepsy in AHID and were eligible for inclusion
i.e. for review of their case-notes over 2006-2009 (Figure 1). Baseline characteristics of 293
participants are listed in Table 1. These were compared to 23.493 individuals, aged 18-75 years, with
an epilepsy code in AHID. Participants in the validation study were slightly younger than the total
cohort of people with an epilepsy code (median age 46 vs. 47 years, p-value 0.003 and more likely to
have an AED prescription (92% vs. 76%, p-value <0.001).
Of the average 3.247.887 people of 18 years and older in AHID during 2006-2009, 24.188 persons per
year had at least one DTP for epilepsy. These numbers were used to estimate prevalence. This does
not equal the total number of people (26.297, of whom 23.493 between 18 and 75 years) found with
an epilepsy code due to variation in the duration of the insurance policy. During the four year period
19% of all insured switched to an alternative insurance provider, emigrated or died. The overall
epilepsy prevalence using DTP codes in AHID was slightly higher than the prevalence rate for the
same codes in the general population (Statistics Netherlands): 7.4/ 1.000 vs. 6.8/1.00 with a
Standardized Prevalence Ratio of 1.08 (95% CI: 1.08-1.09). The prevalence increased with advancing
age in both groups (Table 2).
Of the total 293 cases with an epilepsy code in AHID, 278 were considered to have epilepsy according
to the case-notes (category 1-3). An epilepsy code in AHID accurately predicted a diagnosis of
epilepsy in 95% (PPV) (95% CI: 0.92-0.97), (Table 3). The PPV was 1.0 and 0.85 respectively for a
tertiary epilepsy centre and district hospital). As a sensitivity analysis, we reclassified suspect cases
i.e. we analysed only all definite or probable epilepsy cases (i.e. excluding category 3) and also
including all suspect cases as epilepsy (i.e. including category 4). This resulted in a PPV of 0.93 (95%
CI: 0.89-0.95) and 0.99 (95% CI:0.97-1.00) respectively i.e. only a minor difference when compared to
the originally calculated PPV (0.95).
Discussion
Our findings suggest good validity of an AHID epilepsy code. Previous work also indicated good
validity of administrative diagnostic codes for epilepsy but applied different criteria for case
ascertainment, and used different coding methods and different data sources. (Christensen et al.,
2007; Jette et al., 2010; Lee et al., 2016; Parko and Thurman, 2009; Reid et al., 2012; Tu et al., 2014)
Although mainly all studies used ICD 9 or 10 coding, they applied differences in for example number
and type of visits for their case definition, and codes may have been provided by different health
providers or administrators, which is frequently not mentioned. Coding practice not only varied per
study, but also per country as a result of differences in billing practices, weakening comparisons.
(Thurman et al., 2011) The most accurate algorithm to identify epilepsy cases was found to be 2
physician claims or 1 hospitalization in 2 years coded. (Reid et al., 2012) In our study, we assessed
both in- as well as outpatient diagnostic codes over a period of 4 years, in which >90% had at least 2
diagnostic codes for epilepsy. Ideally, a diagnosis of epilepsy is based on prospective assessment and
includes expert interviews and (video-) EEG-recordings of events. We aimed to account for this
inevitable limitation in diagnostic uncertainty by comparing data from two different sources: a
tertiary epilepsy centre (in which we presumed diagnostic certainty to be above average) and a
district hospital. We found only small differences in validity between both centres (a PPV of 1.00 and
0.85, respectively) suggesting limited bias by diagnostic uncertainty.
Studies also varied in terms of individual selection. We selected those with at least one hospital code
for an epilepsy-related visit as a proxy for the diagnostic codes in the AHID. We therefore could not
determine the negative predictive value of the epilepsy codes in AHID.
In only 5% of our sample the epilepsy codes in AHID did not match the information in case-notes.
Mismatches in coding may be due to diagnostic errors but may also be due to failures in adapting an
initial code, given after the first clinical visit, when, over time, a more appropriate diagnosis emerges.
Assessment of reasons behind the chosen DTP codes was outside the study scope.
The prevalence of (active) epilepsy in The Netherlands as derived from AHID was 7.4/1000 persons.
This was slightly higher than the prevalence of the same codes for the Dutch population. (CBSStatline)
Health care insurance is mandatory in the Netherlands. All insurance companies offer a core
insurance package including epilepsy care at a fixed price, with optional packages for e.g.
physiotherapy, alternative medicine or psychological care without indication or referral by a
physician. Bias based on health status leading to the choice for a certain health insurance company is
thus not likely. The prevalence was also a little higher in comparison to the prevalence of 7.0/ 1000
persons estimated from a sample of GP registries in 2007. (Gommer AM, 2010). Prevalence rates for
active as well as lifetime epilepsy are known to vary, even within studies of similar age groups or
socio-economic level. (Ngugi et al., 2010) There is, thus, no reason to assume that these small
differences in prevalence rates hampered our results with respect to its validity.
Our study may be prone to selection bias due to low participation rate. Yet we consider our sample
size (> 1% of the epilepsy cases in the AHID) combined with the quality of the data suited to assess
the validity of AHID data. Our study population was slightly younger than the average epilepsy
population in the AHID. This might be a proxy for epilepsy severity and willingness to participate in
research. Indeed, there was some bias towards more severe epilepsy cases, as the study sample was
more likely to use AEDs compared to the average epilepsy population in AHID. This may have resulted
in the categorization of more people in group 1-3, but it is unlikely to have influenced our results with
respect to the accuracy of the AHID data, as this is independent of the categorization process itself.
One of the strengths of our study is that it was performed in a country with equal and accessible
healthcare system with abundant available data. (Schoen et al., 2007; Schut and van de Ven, 2011)
The Netherlands has a unique system in which diagnosis and subsequent treatment are combined in
one DTP code, the diagnostic information contained is ICD-based in line with coding applied in most
countries. Another strength includes the fact that codes were inserted by the treating neurologist,
thus contrasting studies where GPs or administrators classified the diagnosis. The Dutch ‘DTP coding’
system has two unique features that avoid false epilepsy codes: 1) special codes are available if no
definite diagnosis can be made (e.g. code for ‘other paroxysmal events’), 2) people can see their own
diagnosis when accessing their health insurance reimbursements. In the Netherlands there is also
relatively little epilepsy-related stigma (Baker et al., 2000; Brigo et al., 2015), which is likely to result
in a more representative sample.
Conclusion
Our findings demonstrates the validity of the Achmea health Insurance database for a diagnosis of
epilepsy, based on a comparison with specialists’ diagnostic information and confirms previous work
on using administrative data for epilepsy research. Dutch health insurance databases, as AHID, may
accurately identify people with epilepsy, based on diagnosis and treatment data, for large scale
epidemiological studies to deepen our understanding in epilepsy-related comorbidity and mortality.
Highlights:
 Achmea is a large Dutch healt insurance company covering about 25 of the population.
 The Achmea Health Insurance data (AHID) can be reliably used to identify people with
epilepsy
 Epilepsy codes in Achmea health data proofed quite accurate (PPV 0.95)
 This confirms previous work on using administrative health data for epilepsy research.
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TABLE 1 Baseline characteristics of the participants in the validation study compared to the people with a









Sex (% males) 143 (49%) 12783 (54%)
Age in 2006 (median, IQR) 46 (34-55) 47 (34-59) 0.003
At least 2 DTP codes for epilepsy (2 or more
epilepsy related visits) in the period 2006-2009
266 (91%) 18143 (77%) <0.001
AED use in the period 2006-2009 269 (92%) 17869 (76%) <0.001
Number of different AED types (average per year)
(median, IQR) in the period 2006-2009
1.3 (1-2) 0.8 (0.3-1) <0.001
TABLE 2: Age-specific prevalence rates for the different age groups AHID vs general Dutch population




18 to 29 years 0.59 0.60** 0.99 (0.97-1.00)
30 to 39 years 0.59 0.55 1.07 (1.05-1.09)
40 to 49 years 0.72 0.63 1.15 (1.13-1.17)
50 to 59 years 0.84 0.75 1.12 (1.10-1.13)
60 to 69 year 0.86 0.81 1.05 (1.04-1.07)
70 to 79 years 0.99 0.94 1.06 (1.04-1.08)
80 years and older 0.87 0.71 1.23 (1.20-1.26)
Total 0.74 0.68 1.08 (1.08-1.09)
* Prevalence calculation based on number of DTPs for epilepsy in the Dutch population; data available for
the period 2008 and 2009 ** age group 15-29 years as data are only provided per 5-year age groups




































































6* 5 1* 11 0 1 24
TOTAL 264 8 6 13 1 1 293
PPV = 0.95
*Non-compliance i.e. AEDs were prescribed by neurologist but never filled
